文献速递胰腺与胆道疾病

卡莫司他治疗疼痛性慢性胰腺炎疗效与安全性的随机对照2期剂量探索试验:TACTIC研究

A Randomized Controlled Phase 2 Dose-Finding Trial to Evaluate the Efficacy and Safety of Camostat in the Treatment of Painful Chronic Pancreatitis: The TACTIC Study.
PubMed 文献 · Gastroenterology · 2023-12-15

这项双盲随机对照2期试验纳入264例疼痛性慢性胰腺炎成人患者,按1:1:1:1随机接受卡莫司他100、200、300 mg每日3次或安慰剂。主要终点4周每日最严重疼痛强度评分变化在各卡莫司他组与安慰剂组间相似,差异均未达统计学显著,次要终点亦无差异;研究药物相关治疗中出现的不良事件见于42例(16.0%)。

要点

  • 卡莫司他100、200、300 mg每日3次与安慰剂相比,4周疼痛评分变化无显著差异。
  • 主要终点最小二乘均值差分别为-0.11、-0.04、-0.11,95%CI均跨0。
  • 研究药物相关治疗中出现的不良事件见于42例(16.0%)。

核心结论

  • 无法拒绝疼痛性慢性胰腺炎患者接受卡莫司他与安慰剂在疼痛或生活质量改善方面无差异的无效假设。
  • 需要开展研究进一步明确慢性胰腺炎疼痛机制,以指导未来临床试验,包括减少安慰剂反应和选择靶向治疗。

研究设计与样本

  • 双盲随机对照2期剂量探索试验,纳入基线平均每日最严重疼痛评分≥4(数字评分系统0-10)的慢性胰腺炎成人患者。
  • 参与者按1:1:1:1随机接受卡莫司他100、200、300 mg每日3次或安慰剂。
  • 共264例慢性胰腺炎参与者被随机分组。
  • 主要终点为采用混合模型重复测量分析评估的每日最严重疼痛强度评分(数字评分系统0-10)均值自基线至4周的变化。

主要发现

  • 卡莫司他组与安慰剂组疼痛自基线变化相似,100 mg、200 mg、300 mg组最小二乘均值差分别为-0.11(95%CI -0.90至0.68)、-0.04(95%CI -0.85至0.78)、-0.11(95%CI -0.94至0.73)。
  • 主要终点的多项亚组分析结果相似。
  • 任何次要终点均未观察到差异。
  • 归因于研究药物的治疗中出现的不良事件见于42例参与者(16.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要开展研究进一步明确慢性胰腺炎疼痛机制,以指导未来临床试验,包括减少安慰剂反应和选择靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic pancreatitis (CP) causes an abdominal pain syndrome associated with poor quality of life. We conducted a clinical trial to further investigate the efficacy and safety of camostat, an oral serine protease inhibitor that has been used to alleviate pain in CP. METHODS: This was a double-blind randomized controlled trial that enrolled adults with CP with a baseline average daily worst pain score ≥4 on a numeric rating system. Participants were randomized (1:1:1:1) to receive camostat at 100, 200, or 300 mg 3 times daily or placebo. The primary end point was a 4-week change from baseline in the mean daily worst pain intensity score (0-10 on a numeric rating system) using a mixed model repeated measure analysis. Secondary end points included changes in alternate pain end points, quality of life, and safety. RESULTS: A total of 264 participants with CP were randomized. Changes in pain from baseline were similar between the camostat groups and placebo, with differences of least squares means of -0.11 (95% CI, -0.90 to 0.68), -0.04 (95% CI, -0.85 to 0.78), and -0.11 (95% CI, -0.94 to 0.73) for the 100 mg, 200 mg, and 300 mg groups, respectively. Multiple subgroup analyses were similar for the primary end point, and no differences were observed in any of the secondary end points. Treatment-emergent adverse events attributed to the study drug were identified in 42 participants (16.0%). CONCLUSION: We were not able to reject the null hypothesis of no difference in improvements in pain or quality of life outcomes in participants with painful CP who received camostat compared with placebo. Studies are needed to further define mechanisms of pain in CP to guide future clinical trials, including minimizing placebo responses and selecting targeted therapies. CLINICALTRIALS: gov, Number: NCT02693093.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hart PA, Osypchuk Y, Hovbakh I, et al. A Randomized Controlled Phase 2 Dose-Finding Trial to Evaluate the Efficacy and Safety of Camostat in the Treatment of Painful Chronic Pancreatitis: The TACTIC Study. Gastroenterology. 2023. PMID: 38103842. doi:10.1053/j.gastro.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。